Forest plots showing hazard ratios obtained by multivariate Cox regression analysis of TUDD (excluding death as event) for EORTC QLQ-C30 scales according to treatment arm.

<p>Forest plots showing hazard ratios obtained by multivariate Cox regression analysis of TUDD (excluding death as event) for EORTC QLQ-C30 scales according to treatment arm.</p

Forest plots showing hazard ratios obtained by univariate Cox regression analysis of TUDD for EORTC QLQ-C30 scales according to treatment arm.

<p>Forest plots showing hazard ratios obtained by univariate Cox regression analysis of TUDD for EORTC QLQ-C30 scales according to treatment arm.</p

Kaplan-Meier survival curves for TUDD according to global health status (A), physical functioning (B), role functioning (C), emotional functioning (D), cognitive functioning (E), social functioning (F) fatigue (G), nausea (H), pain (I), dyspnea (J), insomnia (K), appetite loss (L), constipation (M), and diarrhea (N).

<p>Kaplan-Meier survival curves for TUDD according to global health status (A), physical functioning (B), role functioning (C), emotional functioning (D), cognitive functioning (E), social functioning (F) fatigue (G), nausea (H), pain (I), dyspnea (J), insomnia (K), appetite loss (L), constipation (M), and diarrhea (N).</p

Characteristics of patients who did and did not complete the baseline questionnaire.

<p>Characteristics of patients who did and did not complete the baseline questionnaire.</p

Quality of life score at baseline according to treatment arm.

<p>Quality of life score at baseline according to treatment arm.</p

Forest plots showing hazard ratios obtained by multivariate Cox regression analysis of TUDD (excluding death as event) for EORTC QLQ-C30 scales according to treatment arm.

<p>Forest plots showing hazard ratios obtained by multivariate Cox regression analysis of TUDD (excluding death as event) for EORTC QLQ-C30 scales according to treatment arm.</p

Consort flowchart of the primary objective in the FFCD-1004 clinical trial.

<p>Consort flowchart of the primary objective in the FFCD-1004 clinical trial.</p

Median overall survival according to different criteria.

<p>Median overall survival according to different criteria.</p

Pharmacokinetics profiles of gemcitabine (A) and its metabolite (B) overtime during the first round of gemcitabine administration in pancreatic adenocarcinoma cancer patients.

<p>Patients have been sampled before infusion, at the end, and 90 and 120 minutes after ending the infusion. A wide inter-individual variability is observed, either for gemcitabine or for dFdU.</p

Boxplots of CDA activity in prospective compared to retrospective study.

<p>CDAretro stands for CDA activity in gemcitabine-treated patients for various types of cancers in the retrospective study. The boxplot in the middle represents CDA activity in the subgroup of gemcitabine-monotherapy patients in the retrospective study. CDA activities of patients from the prospective study are represented in the boxplot on the right. Isolating gemcitabine-monotherapy treated patients leads to a smoothing effect in CDA activity variability.</p